Bystolic fulfills pharmacists’ desire for a new beta-blocker
NEW YORK Forest Laboratories and Mylan’s new, once-daily hypertension drug Bystolic now is available in pharmacies nationwide.
A recent survey showed that out of 20,000 retail pharmacists, 78 percent felt there was a need for a beta-blocker with an improved tolerability profile.
More than 2,000 people received Bystolic (nebivolol) during clinical trials. The drug’s efficacy was similar to that of other approved beta-blockers, the FDA said. The most common reported side effects were headache, fatigue, dizziness and diarrhea.
Hypertension affects about 72 million adults in America.
Cobalt dismisses generic Precose lawsuit against FDA
WASHINGTON Cobalt has decided voluntarily to dismiss a lawsuit in which it had asked a court to restore its marketing exclusivity for a generic version of Bayer Pharmaceutical’s diabetes drug Precose.
The company said it was dismissing the case against the Food and Drug Administration without prejudice. Cobalt had brought the suit to the U.S. District Court for the District of Columbia on May 8, alleging the agency had unlawfully forfeited the company’s 180-day marketing exclusivity for a generic version of Precose (acarbose).
Cobalt had maintained that it was the first company to file an application on the drug’s ‘769 patent, which has been removed from the Orange Book. However, the FDA informed Cobalt May 7 that it had forfeited its right to generic exclusivity.
Cobalt said in court documents the FDA acknowledged its actions had delayed the company’s ability to market the product, but the agency said Cobalt had forfeited its exclusivity because it failed to obtain final approval and launch within 30 months of its 2005 application submission.
Cobalt asked the court to enjoin the agency from approving all other applications for the drug “until natural expiration of Cobalt’s statutory right to exclusivity for its acarbose application.” It also requested that the FDA stay or withdraw approval for other acarbose applications, including one from Boehringer Ingelheim’s subsidiary Roxane, which the agency approved May 7. Finally, it asked the court to order the FDA to recall any acarbose product made by Roxane on the market.
The court declined to issue a temporary restraining order against Roxane, finding that under the language of the Food, Drug and Cosmetic Act, Cobalt was unlikely to prevail in the case and Roxane would suffer “significant competitive injury,” Zuckerman Spaeder, the law firm representing Roxane, said.
House releases draft of I.T. legislation
WASHINGTON Rep. John Dingell, D-Mich., chair of the House Energy and Commerce Committee, has released a discussion draft of proposed health care information technology legislation.
Provisions of the draft bill, which contains ideas from at least five House bills introduced during the last two congressional sessions, include the following:
Subject business associates directly to the safeguards in the Health Insurance Portability and Accountability Act privacy and security bills and hold business associates directly accountable to the federal government for violations of minimum contract requirements.
Close a HIPAA loophole that permits disclosure of protected health information for “treatment alternatives.” Authors of the legislation believe providers have used the loophole to send marketing materials to patients without their authorization.
Require regional health information organizations and health information exchanges to have business associate contracts under the privacy rule.
Require personal health record vendors who store the records in one place to notify consumers of data breaches.
Codify, or place into law, the Office of the National Coordinator for Health Information Technology. This would make the position permanent.
Establish two federal advisory committees to prioritize and develop technical data standards.
Establish and fund a health information technology resource center.
Establish grant programs to support provider adoption of I.T., support state-based I.T. loans for provider I.T. adoption, and support local and regional health information exchange initiatives. The discussion draft does not specify funding levels.